Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1972 Jan;44(1):63–70. doi: 10.1111/j.1476-5381.1972.tb07238.x

Relationship between the chemical structure of prostaglandins and their vasoactivities in dogs

J Nakano
PMCID: PMC1665697  PMID: 5015041

Abstract

1. The relationship between the chemical structure and the direct vasoactivity of different prostaglandins administered intra-arterially was studied in the dog hindlimb preparation.

2. All of the prostaglandins studied, except PGF1α and PGF2α, caused a dose related decrease in the femoral arterial perfusion pressure in dogs in which the femoral arterial blood flow was kept constant, indicating the direct vasodilator action of these prostaglandins.

3. Among the prostaglandins studied, PGE1 is the most potent vasodilator. Comparing the chemical structure and vasodilator action of PGE1 with those of different prostaglandins, the following conclusions can be made:

4. The formation of the Δ5 double bond in PGE1 causes no change in its vasodilator activity, whereas the saturation of the Δ13 double bond of PGE1 slightly reduces its activity.

5. The alterations in the orientation and length of the carboxyl and alkyl side chains reduce markedly the vasodilator action of PGE- and PGA-compounds.

6. The presence of a carbonyl group at C9 is the most important requirement for the potent vasodilator action of PGE1. On the other hand, the presence and S-configuration of a hydroxyl group at C15 are essential for the intrinsic action at the receptor sites in the vascular smooth muscle, but may not be responsible for the vasodilator action.

7. The esterification of PGE1 or PGE2 and a triple bond formation and the replacement of C7 with oxygen in prostaglandin appear to reduce or abolish their vasodilator action.

Full text

PDF
63

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anggård E. The biological activities of three metabolites of prostaglandin E 1. Acta Physiol Scand. 1966 Apr;66(4):509–510. doi: 10.1111/j.1748-1716.1966.tb03231.x. [DOI] [PubMed] [Google Scholar]
  2. BERGSTROEM S., EULERUS V. THE BIOLOGICAL ACTIVITY OF PROSTAGLANDIN E1, E2 AND E3. Acta Physiol Scand. 1963 Dec;59:493–494. doi: 10.1111/j.1748-1716.1963.tb02766.x. [DOI] [PubMed] [Google Scholar]
  3. Ducharme D. W., Weeks J. R., Montgomery R. G. Studies on the mechanism of the hypertensive effect of prostaglandin F2-alpha. J Pharmacol Exp Ther. 1968 Mar;160(1):1–10. [PubMed] [Google Scholar]
  4. Ferreira S. H., Vane J. R. Prostaglandins: their disappearance from and release into the circulation. Nature. 1967 Dec 2;216(5118):868–873. doi: 10.1038/216868a0. [DOI] [PubMed] [Google Scholar]
  5. Fried J., Santhanakrishnan T. S., Himizu J., Lin C. H., Ford S. H., Rubin B., Grigas E. O. Prostaglandin antagonists: synthesis and smooth muscle activity. Nature. 1969 Jul 12;223(5202):208–210. doi: 10.1038/223208a0. [DOI] [PubMed] [Google Scholar]
  6. GREEN K., SAMUELSSON B. PROSTAGLANDINS AND RELATED FACTORS: XIX. THIN-LAYER CHROMATOGRAPHY OF PROSTAGLANDINS. J Lipid Res. 1964 Jan;5:117–120. [PubMed] [Google Scholar]
  7. HADDY F. J., MOLNAR J. I., CAMPBELL R. W. Effects of denervation and vasoactive agents on vascular pressures and weight of dog forelimb. Am J Physiol. 1961 Oct;201:631–638. doi: 10.1152/ajplegacy.1961.201.4.631. [DOI] [PubMed] [Google Scholar]
  8. HORTON E. W., MAIN I. H. A COMPARISON OF THE BIOLOGICAL ACTIVITIES OF FOUR PROSTAGLANDINS. Br J Pharmacol Chemother. 1963 Aug;21:182–189. doi: 10.1111/j.1476-5381.1963.tb01514.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Horton E. W., Jones R. L. Prostaglandins A1,A2 and 19-hydroxy A1; their actions on smooth muscle and their inactivation on passage through the pulmonary and hepatic portal vascular beds. Br J Pharmacol. 1969 Nov;37(3):705–722. doi: 10.1111/j.1476-5381.1969.tb08509.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kloeze J. Relationship between chemical structure and platelet-aggregation activity of prostaglandins. Biochim Biophys Acta. 1969 Oct 28;187(3):285–292. doi: 10.1016/0005-2760(69)90001-0. [DOI] [PubMed] [Google Scholar]
  11. Lippmann W. Inhibition of gastric acid secretion in the rat by synthetic prostaglandins. J Pharm Pharmacol. 1969 May;21(5):335–336. doi: 10.1111/j.2042-7158.1969.tb08266.x. [DOI] [PubMed] [Google Scholar]
  12. McGiff J. C., Terragno N. A., Strand J. C., Lee J. B., Lonigro A. J., Ng K. K. Selective passage of prostaglandins across the lung. Nature. 1969 Aug 16;223(5207):742–745. doi: 10.1038/223742b0. [DOI] [PubMed] [Google Scholar]
  13. Nakano J., Anggård E., Samuelsson B. 15-Hydroxy-prostanoate dehydrogenase. Prostaglandins as substrates and inhibitors. Eur J Biochem. 1969 Dec;11(2):386–389. doi: 10.1111/j.1432-1033.1969.tb00784.x. [DOI] [PubMed] [Google Scholar]
  14. Nakano J. Cardiovascular effect of a prostaglandin isolated from a gorgonian Plexaura homomalla. J Pharm Pharmacol. 1969 Nov;21(11):782–783. doi: 10.1111/j.2042-7158.1969.tb08172.x. [DOI] [PubMed] [Google Scholar]
  15. Nakano J., Cole B. Effects of prostaglandins E1 and F2-alpha on systemic, pulmonary, and splanchnic circulations in dogs. Am J Physiol. 1969 Jul;217(1):222–227. doi: 10.1152/ajplegacy.1969.217.1.222. [DOI] [PubMed] [Google Scholar]
  16. Nakano J. Effects of the metabolites of prostaglandin E1 on the systemic and peripheral circulations in dogs. Proc Soc Exp Biol Med. 1971 Apr;136(4):1265–1268. doi: 10.3181/00379727-136-35472. [DOI] [PubMed] [Google Scholar]
  17. Nakano J., Kessinger J. M. Effects of 8-isoprostaglandin E1 on the systemic and pulmonary circulations in dogs. Proc Soc Exp Biol Med. 1970 Apr;133(4):1314–1317. doi: 10.3181/00379727-133-34679. [DOI] [PubMed] [Google Scholar]
  18. Nakano J., McCloy R. B., Jr Effect of quinidine on cardiovascular dynamics. Arch Int Pharmacodyn Ther. 1967 Aug;168(2):400–416. [PubMed] [Google Scholar]
  19. Nakano J., McCurdy J. R. Hemodynamic effects of prostaglandins E1, A1 and F2-alpha in dogs. Proc Soc Exp Biol Med. 1968 May;128(1):39–42. doi: 10.3181/00379727-128-32937. [DOI] [PubMed] [Google Scholar]
  20. Nakano J. Metabolism of prostaglandin E in dog kidneys. Br J Pharmacol. 1970 Oct;40(2):317–325. doi: 10.1111/j.1476-5381.1970.tb09924.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ramwell P. W., Shaw J. E., Corey E. J., Andersen N. Biological activity of synthetic prostaglandins. Nature. 1969 Mar 29;221(5187):1251–1253. doi: 10.1038/2211251b0. [DOI] [PubMed] [Google Scholar]
  22. SAMUELSSON B. ISOLATION AND IDENTIFICATION OF PROSTAGLANDINS FROM HUMAN SEMINAL PLASMA. 18. PROSTAGLANDINS AND RELATED FACTORS. J Biol Chem. 1963 Oct;238:3229–3234. [PubMed] [Google Scholar]
  23. SAMUELSSON B. PROSTAGLANDINS AND RELATED FACTORS. 28. METABOLISM OF PROSTAGLANDIN E1 IN GUINEA PIG LUNG: THE STRUCTURES OF TWO METABOLITES. J Biol Chem. 1964 Dec;239:4097–4102. [PubMed] [Google Scholar]
  24. Weeks J. R., Sekhar N. C., Ducharme D. W. Relative activity of prostaglandins E1, A1, E2 and A2 on lipolysis, platelet aggregation, smooth muscle and the cardiovascular system. J Pharm Pharmacol. 1969 Feb;21(2):103–108. doi: 10.1111/j.2042-7158.1969.tb08205.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES